Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Aug 31;15(4):2002-2005.
doi: 10.21037/jgo-24-255. Epub 2024 Aug 5.

MRTX1133's promise for treating KRASG12D-mutant pancreatic cancer

Malak Haidar  1 , Patrick Jacquemin  1
Affiliations
Editorial

MRTX1133's promise for treating KRASG12D-mutant pancreatic cancer

Malak Haidar et al. J Gastrointest Oncol. .
No abstract available

Keywords: KRAS; MRTX1133; Pancreatic ductal adenocarcinoma (PDAC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-24-255/coif). M.H. is a Research Assistant at the Fonds de la Recherche Scientifique (FNRS) FRS-FNRS. P.J. is a Research Director at FRS-FNRS. The authors have no other conflicts of interest to declare.

Comment on

References

    1. Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, et al. Pancreatic cancer: Advances and challenges. Cell 2023;186:1729-54. 10.1016/j.cell.2023.02.014 - DOI - PMC - PubMed
    1. Ushio J, Kanno A, Ikeda E, et al. Pancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors. Diagnostics (Basel) 2021;11:562. 10.3390/diagnostics11030562 - DOI - PMC - PubMed
    1. Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016;531:47-52. 10.1038/nature16965 - DOI - PubMed
    1. Aung KL, McWhirter E, Welch S, et al. A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. J Gastrointest Oncol 2022;13:3216-26. 10.21037/jgo-22-86 - DOI - PMC - PubMed
    1. Linehan A, O'Reilly M, McDermott R, et al. Targeting KRAS mutations in pancreatic cancer: opportunities for future strategies. Front Med (Lausanne) 2024;11:1369136. 10.3389/fmed.2024.1369136 - DOI - PMC - PubMed